RxDoctor Payments Data

James Maliszewski, MD

Internal Medicine · Omaha, NENPI 1205197464

Payments from drug & device makers

$315in general payments, 2019–2025

Across 20 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$62
  • Pfizer$57
  • Lilly USA, LLC$30
  • Sumitomo Pharma America, Inc.$27
  • Biohaven Pharmaceutical Holding Company Ltd.$18
  • AbbVie$17
  • plus $104 from 7 others

What the payments were for

  • Food & beverage$315100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$315 in reported general payments places this provider in the 65th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$385,449
Medicare patients
529
Services billed
6,644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$166,317
OzempicSemaglutide118$121,665
JardianceEmpagliflozin95$90,364
TrulicityDulaglutide70$70,288
MounjaroTirzepatide36$38,755
XareltoRivaroxaban39$36,159
RybelsusSemaglutide16$24,417
EntrestoSacubitril/Valsartan20$16,968
JanuviaSitagliptin Phosphate17$14,585
FarxigaDapagliflozin Propanediol14$12,265
Xultophy 100-3.6Insulin Degludec/Liraglutide11$9,985
Advair HfaFluticasone Propion/Salmeterol16$9,906
Tresiba Flextouch U-200Insulin Degludec17$9,768
Breo ElliptaFluticasone/Vilanterol12$6,580
Atorvastatin Calcium788$6,088

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$57$169,176145 claims
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$14$156,068145 claims
Lilly USA, LLCTrulicity, Mounjaro$30$109,043106 claims
Boehringer IngelheimJardiance$14$90,36495 claims
Johnson & JohnsonXarelto$15$36,15939 claims
AstraZenecaFarxiga, Symbicort$15$15,52928 claims
AbbVieSynthroid$17$4,36841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →